BWAY

Brainsway Ltd (BWAY) | Rumor.io

Brainsway

BWAY

Attention (50-day avg)0%

Attention rank (50-day avg)#3,324

Bullish sentiment (50-day avg)100%

Price to earnings ratio57.6

Market capitalization533.2M

Earnings per share0.23

Dividend yield (TTM)—

Revenue (annual)52.2M

Net income (annual)7.6M

Social

What share of all stock conversation is about BWAY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% +0

Mar 11

BrainsWay Ltd. reported 27% revenue growth, 10 consecutive profitable quarters, and raised 2026 guidance amid expanding market presence.
The company expects full-year 2026 revenue of $66M to $68M, representing 27% to 30% growth, with operating income targeted at 13% to 14% and Adjusted EBITDA of $12M to $14M.
BrainsWay's Deep TMS therapy has shown strong momentum, with FDA approvals, new clinical trials, and insurers beginning to cover the treatment, supporting commercial adoption and growth catalysts.

Generated by AI

Sentiment

Of the messages about BWAY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	87.93% -7.77
Bearish	—	—	—	12.07% +7.77

Bullish· Aug 29

$BWAY has a buy PT rating for $15 and is considered a better company than $NERV, with a strong cash position.
BrainsWay Ltd. has received FDA clearance for its treatment of depression and anxiety, which is expected to drive significant growth.
The company has a strong financial situation, with $50m in cash and $30m in revenue per year, and is considered undervalued, with a potential for a double-digit run.

Bearish· Aug 29

The stock's FDA clearance news for anxiety and depression may not be enough to sustain its price, given the short attack it received.
The stock's low float and heavy short interest make it vulnerable to further price drops.
The stock's Israeli origin may be a reason for investors to be cautious and potentially lead to a 52-week low.

Generated by AI

Topics

Of the messages about BWAY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	50%	67.86%
Technical Analysis	—	—	0%	14.29%
Analysts	—	—	50%	4.12%
Earnings	—	—	0%	13.74%
Controversies	—	—	0%	0%
Macro	—	—	0%	0%

Announcements· Aug 18

BrainsWay Ltd. ($BWAY) has received FDA approval for its Deep TMS system to treat depression, including decreasing anxiety symptoms in patients.
The company's shares have climbed 20% following the 510(k) clearance for its Deep Transcranial Magnetic Stimulation System to treat symptoms of depression.
BrainsWay's Deep TMS system has been CE-marked in Europe to safely treat various conditions, including Alzheimer's Disease, Autism, and Parkinson's Disease.

Technical Analysis· Aug 18

The RSI for $BWAY seems oversold, but the lack of volume is puzzling given the FDA approval.
A bull flag is forming, with the stock hitting a ceiling and needing to break through to continue upward.
The stock has formed a classic example of a bear flag, with a potential retrace to $8.8 and a possible full breakout at $10.91.

Generated by AI

Community

Of the messages about BWAY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	5.26%	28.48%
Newcomers	100%	100%	94.74%	71.52%

Regulars· Nov 16

BrainsWay Ltd. reported a loss of $0.15 per share, missing consensus estimates by $0.08.
The company's Q3 2022 GAAP EPS and revenue both missed expectations, with GAAP EPS of -$0.15 and revenue of $5.17M.
BrainsWay's stock price has dropped by $-0.35 (-10.94%) to $2.85, with the stochastic indicator suggesting the stock may be in an uptrend.

Newcomers· Aug 29

BrainsWay Ltd. ($BWAY) gained about 25% premarket after receiving FDA clearance for depression treatment, according to a recent market update.
Some investors have set buy price targets for $BWAY, with one user assigning a target of $15, while others have identified resistance and support levels for the stock.
A trader who attempted to sell on a gap and close (G/C) setup for $BWAY was able to hold profits after the tape indicated a favorable market condition.

Generated by AI

News

BrainsWay: Execution Isn’t The Problem, Market Size Is (NASDAQ:BWAY)

7d agoSeeking Alpha

Analysts Offer Insights on Healthcare Companies: Brainsway (BWAY), Cooper Co (COO) and Arcus Biosciences (RCUS)

Detailed price information for Cooper Companies (COO-Q) from The Globe and Mail including charting and trades.

19d agotheglobeandmail.com

BrainsWay’s (BWAY) Growth Streak Just Got Harder To Ignore

On August 12, BrainsWay Ltd. (NASDAQ:BWAY) reported second-quarter 2026 results that make the neurostimulation company look less like a niche medtech story and more like a genuine growth compounder. Revenue climbed 35% year over year to a record $17.1 million, and adjusted EBITDA more than doubled to $3.5 million. The company shipped 125 Deep TMS […]

19d agoYahoo! Finance Canada

Are Options Traders Betting on a Big Move in Brainsway Stock?

Investors need to pay close attention to BWAY stock based on the movements in the options market lately.

21d agofinance.yahoo.com

BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™

22d agofinance.yahoo.com

H.C. Wainwright raises Brainsway stock price target on new data

1mo agoInvesting.com

Also Discussed

Investors talking about BWAY also mention

#	Name	Attention
1	Neuronetics Inc.STIM	0%0
2	Virpax Pharmaceuticals Inc.VRPX	0%0
3	EUDA Health Holdings LimitedEUDA	0%new
4	PharmaCyte Biotech, Inc.PMCB	0%0
5	Orla Mining Ltd.ORLA	0%0
6	Consumer Portfolio Services, Inc. Common StockCPSS	0%0
7	Nortech Systems IncorporatedNSYS	0%0
8	PodcastOne, Inc. Common StockPODC	0%0
9	Commercial Vehicle Group IncCVGI	0%0
10	KALV - KalVista Pharmaceuticals, Inc.	——

Brainsway Ltd

Healthcare
Medical Devices

BrainsWay Ltd. Sponsored ADR is a medical technology company focused on non-invasive neurostimulation treatments for brain and mental health disorders. BrainsWay develops and commercializes its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) systems, which use magnetic pulses to stimulate targeted brain regions and support treatment for conditions such as major depressive disorder and obsessive-compulsive disorder. The company’s products are used in psychiatric and clinical settings, serving physicians, hospitals, and medical centers that incorporate device-based therapies into patient care. BrainsWay also addresses broader neurological and mental health applications through its commercial treatment platforms and related services. Headquartered in Jerusalem, Israel, BrainsWay operates as a specialized healthcare equipment provider with a focus on advanced brain stimulation technologies and the clinical markets that use them.

Website

Location

16 Hartum St

Jerusalem, 9777516

Israel

Social

What share of all stock conversation is about BWAY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% +0

Mar 11

BrainsWay Ltd. reported 27% revenue growth, 10 consecutive profitable quarters, and raised 2026 guidance amid expanding market presence.
The company expects full-year 2026 revenue of $66M to $68M, representing 27% to 30% growth, with operating income targeted at 13% to 14% and Adjusted EBITDA of $12M to $14M.
BrainsWay's Deep TMS therapy has shown strong momentum, with FDA approvals, new clinical trials, and insurers beginning to cover the treatment, supporting commercial adoption and growth catalysts.

Generated by AI

Sentiment

Of the messages about BWAY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	87.93% -7.77
Bearish	—	—	—	12.07% +7.77

Bullish· Aug 29

$BWAY has a buy PT rating for $15 and is considered a better company than $NERV, with a strong cash position.
BrainsWay Ltd. has received FDA clearance for its treatment of depression and anxiety, which is expected to drive significant growth.
The company has a strong financial situation, with $50m in cash and $30m in revenue per year, and is considered undervalued, with a potential for a double-digit run.

Bearish· Aug 29

The stock's FDA clearance news for anxiety and depression may not be enough to sustain its price, given the short attack it received.
The stock's low float and heavy short interest make it vulnerable to further price drops.
The stock's Israeli origin may be a reason for investors to be cautious and potentially lead to a 52-week low.

Generated by AI

Topics

Of the messages about BWAY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	50%	67.86%
Technical Analysis	—	—	0%	14.29%
Analysts	—	—	50%	4.12%
Earnings	—	—	0%	13.74%
Controversies	—	—	0%	0%
Macro	—	—	0%	0%

Announcements· Aug 18

BrainsWay Ltd. ($BWAY) has received FDA approval for its Deep TMS system to treat depression, including decreasing anxiety symptoms in patients.
The company's shares have climbed 20% following the 510(k) clearance for its Deep Transcranial Magnetic Stimulation System to treat symptoms of depression.
BrainsWay's Deep TMS system has been CE-marked in Europe to safely treat various conditions, including Alzheimer's Disease, Autism, and Parkinson's Disease.

Technical Analysis· Aug 18

The RSI for $BWAY seems oversold, but the lack of volume is puzzling given the FDA approval.
A bull flag is forming, with the stock hitting a ceiling and needing to break through to continue upward.
The stock has formed a classic example of a bear flag, with a potential retrace to $8.8 and a possible full breakout at $10.91.

Generated by AI

Community

Of the messages about BWAY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	5.26%	28.48%
Newcomers	100%	100%	94.74%	71.52%

Regulars· Nov 16

BrainsWay Ltd. reported a loss of $0.15 per share, missing consensus estimates by $0.08.
The company's Q3 2022 GAAP EPS and revenue both missed expectations, with GAAP EPS of -$0.15 and revenue of $5.17M.
BrainsWay's stock price has dropped by $-0.35 (-10.94%) to $2.85, with the stochastic indicator suggesting the stock may be in an uptrend.

Newcomers· Aug 29

BrainsWay Ltd. ($BWAY) gained about 25% premarket after receiving FDA clearance for depression treatment, according to a recent market update.
Some investors have set buy price targets for $BWAY, with one user assigning a target of $15, while others have identified resistance and support levels for the stock.
A trader who attempted to sell on a gap and close (G/C) setup for $BWAY was able to hold profits after the tape indicated a favorable market condition.

Generated by AI

Brainsway

Social

Mar 11

Bullish· Aug 29

Bearish· Aug 29

Announcements· Aug 18

Technical Analysis· Aug 18

Regulars· Nov 16

Newcomers· Aug 29

BrainsWay: Execution Isn’t The Problem, Market Size Is (NASDAQ:BWAY)

Analysts Offer Insights on Healthcare Companies: Brainsway (BWAY), Cooper Co (COO) and Arcus Biosciences (RCUS)

BrainsWay’s (BWAY) Growth Streak Just Got Harder To Ignore

Are Options Traders Betting on a Big Move in Brainsway Stock?

BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™

H.C. Wainwright raises Brainsway stock price target on new data

Also Discussed

Brainsway Ltd

Company Information

Location

BrainsWay: Execution Isn’t The Problem, Market Size Is (NASDAQ:BWAY)

Analysts Offer Insights on Healthcare Companies: Brainsway (BWAY), Cooper Co (COO) and Arcus Biosciences (RCUS)

BrainsWay’s (BWAY) Growth Streak Just Got Harder To Ignore

Are Options Traders Betting on a Big Move in Brainsway Stock?

BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™

H.C. Wainwright raises Brainsway stock price target on new data

Also Discussed

Social

Mar 11

Bullish· Aug 29

Bearish· Aug 29

Announcements· Aug 18

Technical Analysis· Aug 18

Regulars· Nov 16

Newcomers· Aug 29